PT-141 (Bremelanotide) Adult Dosing for Ages 30, 49

FDA-Approved Dose: 1.75 mg Subcutaneous, As Needed

Bremelanotide received FDA approval in June 2019 under the brand name Vyleesi for the treatment of acquired, generalized HSDD in premenopausal women. The approved dose is a single 1.75 mg subcutaneous injection delivered to the abdomen via a prefilled autoinjector. This dose was selected based on Phase 3 data from the RECONNECT trials, which randomized 1,247 premenopausal women with HSDD to bremelanotide 1.75 mg or placebo over 24 weeks [1].

There is no weight-based dosing. There is no titration schedule. The 1.75 mg dose is fixed across all approved patients, and the FDA prescribing label does not call for dose reduction or escalation based on response [2]. For adults in the 30, 49 age bracket without hepatic or renal impairment, the standard dose applies without modification.

Off-label use for male erectile dysfunction exists in clinical practice, though no large randomized trial has validated a specific dose for this population. Prescribers working off-label often use the same 1.75 mg dose, but this practice lacks the regulatory evidence base that supports the approved female indication.

How the RECONNECT Trials Defined Efficacy at This Dose

The RECONNECT program consisted of two identically designed, randomized, double-blind, placebo-controlled Phase 3 trials. Across both studies, bremelanotide 1.75 mg produced a statistically significant increase in the Female Sexual Function Index desire domain score compared with placebo (mean change from baseline: +0.5 vs. +0.2, P<0.001) [1]. Satisfying sexual events increased by a mean of 1.0 per month over placebo.

The mean age of enrolled participants was 39.5 years, placing the majority squarely in the 30, 49 bracket this guide addresses. A subgroup analysis showed no significant interaction between age and treatment effect within the premenopausal population, meaning that a 32-year-old and a 47-year-old derived comparable benefit at the same 1.75 mg dose [1].

The RECONNECT data also tracked distress reduction using the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). Bremelanotide reduced distress scores by a mean of 10.4 points versus 7.6 for placebo. That 2.8-point difference matters clinically because FSDS-DAO thresholds for "meaningful improvement" start at approximately 2 points, per the instrument's validation studies.

Injection Timing and Technique

Patients self-administer bremelanotide using a single-dose, prefilled autoinjector. The injection goes into the subcutaneous tissue of the abdomen, rotating sites to avoid lipodystrophy. The prescribing information specifies at least 45 minutes before anticipated sexual activity, though peak plasma concentration (Tmax) occurs at approximately 1 hour post-dose in pharmacokinetic studies [2].

Practical guidance for the 30, 49 age group: plan the injection 60 minutes before activity if possible. Many patients in this demographic manage complex schedules involving work, children, or both. Dosing flexibility matters. The drug's effect window extends well beyond the 1-hour Tmax. Bremelanotide has a terminal half-life of approximately 2.7 hours, and sexual function improvements have been reported for up to 6 to 8 hours post-injection in patient surveys, though this extended window has not been formally studied in controlled settings.

Store the autoinjector in its original carton at room temperature (20, 25°C). Do not freeze. Each autoinjector is single-use and should be discarded in a sharps container after injection.

Monthly Dose Cap: Why Eight Doses Matter

The FDA label restricts use to no more than eight doses per calendar month. This limit was not derived from a toxicity signal at higher frequencies but rather from the design of the RECONNECT trials, where the mean number of doses used per month was approximately 2.5, 3. The FDA review notes that long-term cardiovascular data beyond this exposure level do not exist [3].

For adults 30, 49, the eight-dose cap is particularly relevant. Younger patients with more frequent sexual activity may find this limit constraining. The clinical reality is straightforward: bremelanotide is designed for episodic, as-needed use, not daily therapy. Patients who require more consistent support for sexual desire may need a different treatment approach, such as flibanserin (Addyi), which is taken daily.

Blood Pressure Monitoring Before and After First Dose

Bremelanotide is a melanocortin-4 receptor agonist. Activation of MC4R in the central nervous system mediates its pro-sexual effects, but peripheral MC4R activation also raises blood pressure transiently. In RECONNECT, bremelanotide increased systolic blood pressure by a mean of 3.1 mmHg and diastolic by 1.5 mmHg, peaking at 2 to 3 hours post-dose and resolving within 12 hours [1].

The prescribing label requires blood pressure measurement before prescribing and recommends monitoring in patients with cardiovascular risk factors. Adults 30, 49 represent a transitional decade for cardiovascular health. Hypertension prevalence among U.S. adults aged 35, 44 is approximately 22.4%, per CDC NHANES data, rising to 32.4% among those aged 45, 54 [4]. Prescribers should confirm that resting blood pressure is below 140/90 mmHg before initiating bremelanotide.

Bremelanotide is contraindicated in patients with uncontrolled hypertension and in those with known cardiovascular disease. The label specifically warns against use in patients who have had a myocardial infarction or stroke within the prior 6 months.

Nausea: The Dominant Side Effect and How to Manage It

Nausea affected 40.0% of bremelanotide-treated patients in the RECONNECT trials versus 1.3% on placebo [1]. This is by far the most common adverse event and the primary reason patients discontinue the drug. Vomiting occurred in 5% of the active group.

The Endocrine Society clinical commentary on female sexual dysfunction pharmacotherapy notes that nausea with bremelanotide is dose-dependent and typically diminishes with repeated use over the first few administrations [5]. Practical recommendations for adult patients include:

Eat a light meal 1 to 2 hours before injection. Avoid dosing on a completely empty stomach. Some clinicians prescribe ondansetron 4 mg orally 30 minutes before the bremelanotide injection for the first 3, 4 uses, tapering off as tolerance develops. This is off-label but widely practiced.

Other reported side effects include flushing (20%), injection site reactions (13%), and headache (11%). Hyperpigmentation of the face, gums, and breasts has been reported with repeated dosing. The FDA label notes that skin darkening may not fully resolve after discontinuation.

Off-Label Use in Men: What the Evidence Shows

PT-141 gained early attention through Phase 2 studies in male erectile dysfunction before the RECONNECT program shifted focus to HSDD in women. A Phase 2B trial published by Diamond et al. evaluated intranasal bremelanotide in 342 men with ED and found that 40% of attempts resulted in an erection sufficient for intercourse at the highest dose tested, compared with 22.6% for placebo [6].

The intranasal formulation was ultimately abandoned after the FDA raised concerns about blood pressure elevations at the higher intranasal doses. The subcutaneous formulation used in Vyleesi produces more predictable pharmacokinetics and lower peak blood pressure effects.

No Phase 3 trial of bremelanotide for male ED has been completed. Prescribers who use the 1.75 mg subcutaneous dose off-label in men are extrapolating from the female data and early-phase male studies. Men aged 30, 49 considering this option should understand that insurance will not cover off-label use, and the evidence base is limited to small, older studies.

As the American Urological Association guidelines on ED note, first-line therapy remains PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil), with bremelanotide not yet included in any major guideline algorithm for male sexual dysfunction [7].

Drug Interactions and Contraindications in the 30, 49 Age Group

Bremelanotide has no significant cytochrome P450 interactions, which simplifies prescribing in adults who may be taking SSRIs, hormonal contraceptives, or other common medications. The prescribing information notes one clinically relevant interaction: bremelanotide slows gastric emptying and may reduce the absorption rate of orally administered medications taken around the time of injection [2].

The label specifically warns against taking bremelanotide with naltrexone. Bremelanotide may decrease the systemic exposure of naltrexone, potentially reducing the efficacy of naltrexone-based therapies for alcohol use disorder or opioid dependence.

Contraindications include:

• Uncontrolled hypertension (systolic ≥140 or diastolic ≥90 mmHg)
• Known cardiovascular disease
• Use within 6 months of myocardial infarction or stroke
• Concurrent naltrexone therapy

For women aged 30, 49 who are using hormonal contraceptives, no dose adjustment of either bremelanotide or the contraceptive is required. Bremelanotide is not indicated during pregnancy and should be discontinued if pregnancy is suspected.

Renal and Hepatic Impairment Dosing

Bremelanotide is a peptide cleared primarily through proteolytic degradation rather than hepatic metabolism or renal excretion. The FDA clinical pharmacology review found no clinically meaningful changes in bremelanotide exposure in patients with mild-to-moderate renal impairment (eGFR 30 to 89 mL/min) or mild hepatic impairment (Child-Pugh A) [3].

The drug has not been studied in severe renal impairment (eGFR <30), end-stage renal disease, or moderate-to-severe hepatic impairment (Child-Pugh B or C). Prescribers should avoid use in these populations until data become available. For the typical adult aged 30, 49 with normal organ function, no adjustment is needed.

Comparing Bremelanotide to Flibanserin in This Age Group

Two drugs are FDA-approved for premenopausal HSDD: bremelanotide (Vyleesi) and flibanserin (Addyi). The choice between them often comes down to dosing preference and side-effect tolerance.

Flibanserin is taken as a 100 mg oral tablet daily at bedtime. It requires 4 to 8 weeks of continuous dosing before clinical effect and carries a boxed warning about hypotension and syncope when combined with alcohol [8]. Bremelanotide is as-needed, with same-day onset but prominent nausea.

For adults 30, 49 who consume alcohol socially, bremelanotide avoids the alcohol restriction entirely. For those who prefer not to self-inject, flibanserin offers an oral option. Neither drug has demonstrated superiority over the other in a head-to-head trial. The NEJM review of HSDD therapeutics by Goldstein et al. noted that both agents produce modest but statistically significant improvements in desire, with effect sizes in the range of 0.3, 0.5 on standardized scales [9].

A 30, 49-year-old patient starting treatment should discuss both options with her prescriber, factoring in alcohol use, injection comfort, desire for on-demand versus daily dosing, and nausea tolerance.

Monitoring and Follow-Up Schedule

After initiating bremelanotide, clinicians should reassess at 8 weeks. The RECONNECT trials showed separation from placebo by week 4, with continued improvement through week 24 [1]. If a patient has used the drug at least four times and reports no meaningful change in desire or satisfying sexual events, continued use is unlikely to help.

Blood pressure should be rechecked at the 8-week visit. Skin examination for hyperpigmentation is recommended at each follow-up. If darkening of facial skin, gums, or breast tissue develops and is bothersome, discontinuation should be discussed.

For adults 30, 49 who respond well, annual cardiovascular risk assessment and blood pressure monitoring are reasonable, following standard USPSTF hypertension screening recommendations for this age group: screening every 3 to 5 years if normal, annually if elevated [10].